{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:13:12Z","timestamp":1780549992747,"version":"3.54.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,6,29]],"date-time":"2019-06-29T00:00:00Z","timestamp":1561766400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,29]],"date-time":"2019-06-29T00:00:00Z","timestamp":1561766400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s13139-019-00602-0","type":"journal-article","created":{"date-parts":[[2019,6,29]],"date-time":"2019-06-29T16:02:31Z","timestamp":1561824151000},"page":"263-269","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Predictive Value of Interim and End-of-Therapy 18F-FDG PET\/CT in Patients with Follicular Lymphoma"],"prefix":"10.1007","volume":"53","author":[{"given":"Sun Ha","family":"Boo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6568-5915","authenticated-orcid":false,"given":"Joo Hyun","family":"O","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Jin","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ie Ryung","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyeong Sin","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Ock","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Eun","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok-Goo","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,29]]},"reference":[{"key":"602_CR1","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1038\/bjc.2015.94","volume":"112","author":"A Smith","year":"2015","unstructured":"Smith A, Crouch S, Lax S, Li J, Painter D, Howell D, et al. Lymphoma incidence, survival and prevalence 2004\u20132014: sub-type analyses from the UK\u2019s haematological malignancy research network. Br J Cancer. 2015;112:1575.","journal-title":"Br J Cancer"},{"key":"602_CR2","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3322\/caac.21357","volume":"66","author":"LR Teras","year":"2016","unstructured":"Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66:443\u201359.","journal-title":"CA Cancer J Clin"},{"key":"602_CR3","volume-title":"Goldman-Cecil medicine. 25th edition. Ed","author":"L Goldman","year":"2016","unstructured":"Goldman L, Schafer AI. Goldman-Cecil medicine. 25th edition. Ed. Philadelphia: Elsevier\/Saunders; 2016."},{"key":"602_CR4","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/j.1365-2141.2011.08969.x","volume":"156","author":"C McNamara","year":"2012","unstructured":"McNamara C, Davies J, Dyer M, Hoskin P, Illidge T, Lyttelton M, et al. Guidelines on the investigation and management of follicular lymphoma. Br J Haematol. 2012;156:446\u201367.","journal-title":"Br J Haematol"},{"key":"602_CR5","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201368.","journal-title":"J Clin Oncol"},{"key":"602_CR6","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1080\/10428190903040048","volume":"50","author":"M Meignan","year":"2009","unstructured":"Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET scan in lymphoma. Leuk Lymphoma. 2009;50:1257\u201360.","journal-title":"Leuk Lymphoma"},{"key":"602_CR7","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3816\/CLM.2008.n.040","volume":"8","author":"A Janikova","year":"2008","unstructured":"Janikova A, Bolcak K, Pavlik T, Mayer J, Kral Z. Value of [18F] fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: the end of a dilemma? Clin Lymphoma Myeloma. 2008;8:287\u201393.","journal-title":"Clin Lymphoma Myeloma"},{"key":"602_CR8","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1007\/s00259-010-1539-5","volume":"37","author":"L Le Dortz","year":"2010","unstructured":"Le Dortz L, De Guibert S, Bayat S, Devillers A, Houot R, Rolland Y, et al. Diagnostic and prognostic impact of 18F-FDG PET\/CT in follicular lymphoma. Eur J Nucl Med Mol Imaging. 2010;37:2307\u201314.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"602_CR9","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1093\/annonc\/mdt137","volume":"24","author":"S Luminari","year":"2013","unstructured":"Luminari S, Biasoli I, Arcaini L, Versari A, Rusconi C, Merli F, et al. The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. Ann Oncol. 2013;24:2108\u201312.","journal-title":"Ann Oncol"},{"key":"602_CR10","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ijrobp.2007.09.051","volume":"71","author":"A Wirth","year":"2008","unstructured":"Wirth A, Foo M, Seymour JF, Macmanus MP, Hicks RJ. Impact of [18f] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2008;71:213\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"602_CR11","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1080\/10428190701422059","volume":"48","author":"S Bishu","year":"2007","unstructured":"Bishu S, Quigley JM, Bishu SR, Olsasky SM, Stem RA, Shostrom VK, et al. Predictive value and diagnostic accuracy of F-18-fluoro-deoxy-glucose positron emission tomography treated grade 1 and 2 follicular lymphoma. Leuk Lymphoma. 2007;48:1548\u201355.","journal-title":"Leuk Lymphoma"},{"key":"602_CR12","doi-asserted-by":"publisher","first-page":"4317","DOI":"10.1200\/JCO.2012.43.0934","volume":"30","author":"J Dupuis","year":"2012","unstructured":"Dupuis J, Berriolo-Riedinger A, Julian A, Brice P, Tychyj-Pinel C, Tilly H, et al. Impact of [(18)F] fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte and GOELAMS. J Clin Oncol. 2012;30:4317\u201322.","journal-title":"J Clin Oncol"},{"key":"602_CR13","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1007\/s00259-012-2079-y","volume":"39","author":"E Lopci","year":"2012","unstructured":"Lopci E, Zanoni L, Chiti A, Fonti C, Santi I, Zinzani PL, et al. FDG PET\/CT predictive role in follicular lymphoma. Eur J Nucl Med Mol Imaging. 2012;39:864\u201371.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"602_CR14","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s12149-014-0874-1","volume":"28","author":"Z Lu","year":"2014","unstructured":"Lu Z, Lin M, Downe P, Chong S, Ling S. The prognostic value of mid- and post-treatment [(18)F] fluorodeoxyglucose (FDG) positron emission tomography (PET) in indolent follicular lymphoma. Ann Nucl Med. 2014;28:805\u201311.","journal-title":"Ann Nucl Med"},{"key":"602_CR15","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1093\/annonc\/mdt562","volume":"25","author":"S Luminari","year":"2014","unstructured":"Luminari S, Biasoli I, Versari A, Rattotti S, Bottelli C, Rusconi C, et al. The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL). Ann Oncol. 2014;25:442\u20137.","journal-title":"Ann Oncol"},{"key":"602_CR16","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1200\/JCO.2011.35.0736","volume":"29","author":"J Trotman","year":"2011","unstructured":"Trotman J, Fournier M, Lamy T, Seymour JF, Sonet A, Janikova A, et al. Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. J Clin Oncol. 2011;29:3194\u2013200.","journal-title":"J Clin Oncol"},{"key":"602_CR17","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3816\/CLM.2007.n.005","volume":"7","author":"PL Zinzani","year":"2007","unstructured":"Zinzani PL, Musuraca G, Alinari L, Fanti S, Tani M, Stefoni V, et al. Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma. Clin Lymphoma Myeloma. 2007;7:291\u20135.","journal-title":"Clin Lymphoma Myeloma"},{"key":"602_CR18","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1016\/S2352-3026(14)70008-0","volume":"1","author":"J Trotman","year":"2014","unstructured":"Trotman J, Luminari S, Boussetta S, Versari A, Dupuis J, Tychyj C, et al. Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies. Lancet Haematol. 2014;1:e17\u201327.","journal-title":"Lancet Haematol"},{"key":"602_CR19","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles G, Seymour JF, Offner F, Lopez-Guillermo A, Belada D, Xerri L, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377:42\u201351.","journal-title":"Lancet."},{"issue":"Suppl 3","key":"602_CR20","doi-asserted-by":"publisher","first-page":"iii76","DOI":"10.1093\/annonc\/mdu200","volume":"25","author":"M Dreyling","year":"2014","unstructured":"Dreyling M, Ghielmini M, Marcus R, Salles G, Vitolo U, Ladetto M. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii76\u201382.","journal-title":"Ann Oncol"},{"key":"602_CR21","doi-asserted-by":"publisher","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","volume":"117","author":"E Campo","year":"2011","unstructured":"Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117:5019\u201332.","journal-title":"Blood."},{"key":"602_CR22","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1093\/annonc\/mdq574","volume":"22","author":"J Shustik","year":"2010","unstructured":"Shustik J, Quinn M, Connors JM, Gascoyne RD, Skinnider B, Sehn LH. Follicular non-Hodgkin lymphoma grades 3A and 3B have a similar outcome and appear incurable with anthracycline-based therapy. Ann Oncol. 2010;22:1164\u20139.","journal-title":"Ann Oncol"},{"key":"602_CR23","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/j.1365-2141.2011.08942.x","volume":"156","author":"BE Wahlin","year":"2012","unstructured":"Wahlin BE, Yri OE, Kimby E, Holte H, Delabie J, Smeland EB, et al. Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times. Br J Haematol. 2012;156:225\u201333.","journal-title":"Br J Haematol"},{"key":"602_CR24","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","volume":"34","author":"M Meignan","year":"2016","unstructured":"Meignan M, Cottereau AS, Versari A, Chartier L, Dupuis J, Boussetta S, et al. Baseline metabolic tumor volume predicts outcome in high\u2013tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies. J Clin Oncol. 2016;34:3618\u201326.","journal-title":"J Clin Oncol"},{"key":"602_CR25","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","volume":"25","author":"ME Juweid","year":"2007","unstructured":"Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in lymphoma. J Clin Oncol. 2007;25:571\u20138.","journal-title":"J Clin Oncol"},{"key":"602_CR26","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s13139-015-0368-7","volume":"50","author":"U Metser","year":"2016","unstructured":"Metser U, Mohan R, Beckley V, Moshonov H, Hodgson D, Murphy G. FDG PET\/CT response assessment criteria for patients with Hodgkin\u2019s and non-Hodgkin\u2019s lymphoma at end of therapy: a multiparametric approach. Nucl Med Mol Imaging. 2016;50:46\u201353.","journal-title":"Nucl Med Mol Imaging"},{"key":"602_CR27","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s13139-018-0543-8","volume":"52","author":"HJ Kim","year":"2018","unstructured":"Kim HJ, Lee R, Choi H, Paeng JC, Cheon GJ, Lee DS, et al. Application of quantitative indexes of FDG PET to treatment response evaluation in indolent lymphoma. Nucl Med Mol Imaging. 2018;52:342\u20139.","journal-title":"Nucl Med Mol Imaging"},{"key":"602_CR28","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1007\/s00259-013-2435-6","volume":"40","author":"E Itti","year":"2013","unstructured":"Itti E, Meignan M, Berriolo-Riedinger A, Biggi A, Cashen AF, Vera P, et al. An international confirmatory study of the prognostic value of early PET\/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and DeltaSUVmax. Eur J Nucl Med Mol Imaging. 2013;40:1312\u201320.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"602_CR29","doi-asserted-by":"publisher","first-page":"683","DOI":"10.2967\/jnumed.112.110890","volume":"54","author":"A Biggi","year":"2013","unstructured":"Biggi A, Gallamini A, Chauvie S, Hutchings M, Kostakoglu L, Gregianin M, et al. International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. J Nucl Med. 2013;54:683\u201390.","journal-title":"J Nucl Med"},{"key":"602_CR30","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1182\/blood-2011-06-359943","volume":"119","author":"P Pregno","year":"2012","unstructured":"Pregno P, Chiappella A, Bello M, Botto B, Ferrero S, Franceschetti S, et al. Interim 18-FDG-PET\/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood. 2012;119:2066\u201373.","journal-title":"Blood"},{"key":"602_CR31","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","volume":"374","author":"P Johnson","year":"2016","unstructured":"Johnson P, Federico M, Kirkwood A, Foss\u00e5 A, Berkahn L, Carella A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma. N Engl J Med. 2016;374:2419\u201329.","journal-title":"N Engl J Med"}],"container-title":["Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13139-019-00602-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13139-019-00602-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13139-019-00602-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T23:29:14Z","timestamp":1593300554000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13139-019-00602-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,29]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["602"],"URL":"https:\/\/doi.org\/10.1007\/s13139-019-00602-0","relation":{},"ISSN":["1869-3474","1869-3482"],"issn-type":[{"value":"1869-3474","type":"print"},{"value":"1869-3482","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,29]]},"assertion":[{"value":"18 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Sun Ha Boo, Joo Hyun O, Soo Jin Kwon, Ie Ryung Yoo, Sung Hoon Kim, , Byung Ock Choi, Seung Eun Jung, Seok-Goo Cho declare that they have no conflict of interest. There is no source of funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The Institutional Review Board of our institute approved this retrospective study, and the requirement to obtain informed consent was waived.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}